{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-052741","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.864255+00:00","generated_at":"2026-05-16T02:27:13.746441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEAYA expects topline PFS data from darovasertib Phase 2/3 trial by late March 2026","bullets":["130 required PFS events confirmed by BICR; topline results from OptimUM-02 trial (1L HLA*A2-negative mUM) expected ~last week of March 2026.","Cash, cash equivalents and marketable securities ~$1.05B as of Dec 31, 2025; expected to fund operations into 2030.","Q4 2025 net loss $83.3M vs $130.3M in Q4 2024; R&D expenses $86.6M, down from $140.2M (prior Q4 included $75M license payment to Hengrui).","GSK terminated Collaboration Agreement; Werner Helicase (IDE275) and Pol Theta (IDE705) programs to be transferred to IDEAYA.","Anticipates initiation of IDE849 monotherapy registrational study in 2L+ SCLC/NEC by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-052741","json":"https://secwatch.observer/filing/0001193125-26-052741.json","markdown":"https://secwatch.observer/filing/0001193125-26-052741.md","text":"https://secwatch.observer/filing/0001193125-26-052741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/0001193125-26-052741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:27:13.746441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}